[Furosemide-amiloride combination in the treatment of ascitic-edema in patients with hepatic cirrhosis].
The combination of furosemide-amiloride was used in the management of fluid retention in 16 cirrhotic patients. The study lasted 60 days. In 15 out of the 16 patients a clinical response was observed, namely increased urinary volumen and reduction of abdominal girth. The body weight was reduced by a mean of 7.7 Kg. Serum potassium rose, within normal limits, in 14 patients and a reduction of urinary potassium elimination was observed. Mild hepatic encephalopathy was noticeable in 3 cases, rapidly responding to treatment reduction or withdrawal. The combination of furosemide-amiloride seems to be of value in the management of fluid retention in liver cirrhosis and is uncommonly associated to side effects.
D000328:Adult; D000368:Aged; D000584:Amiloride / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004487:Edema / Q000188:drug therapy; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008104:Liver Cirrhosis, Alcoholic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*; D013607:Tablets
D011719:Pyrazines; D013607:Tablets; D000584:Amiloride; D005665:Furosemide
Uso de la combinación furosemida-amilorida en el tratamiento de la ascitis-edema en pacientes con cirrosis hepática.